Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
106.93
(
0.00%
)
Bitcoin
70,608.01
(
0.13%
)
News Focus
News Focus
Post# of 257266
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ghmm post# 116041

Monday, 03/07/2011 5:43:16 PM

Monday, March 07, 2011 5:43:16 PM

Post# of 257266

I take it that presuming VRTX and MRK get their [HCV] compounds approved, future trials will have to compare to one of the PI's+PEG/Riba?

In the genotype-1 first-line setting, the answer is almost certainly yes. In the genotype-1 second-line setting, the answer is maybe. For non-genotype-1 patients, the answer is no.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today